Cardiovascular polypill,
does it really help with Primary prevention in people without cardiovascular disease?
research showsThe grade is B. In TIPS-3, simvastatin 40 mg, atenolol 100 mg, hydrochlorothiazide 25 mg, and ramipril 10 mg reduced major cardiovascular events over a mean 4.6 years, 4.4% versus 5.5%, HR 0.79 (95% CI 0.63-1.00). The polypill itself did not contain aspirin; aspirin 75 mg was randomized separately.
ads claimThis is primary prevention, unlike post-myocardial-infarction secondary prevention. Verdict 1811 is B with 76 points and addresses recurrent events after myocardial infarction.
Useful facts when choosing a product
- One daily pill contained simvastatin 40 mg, atenolol 100 mg, hydrochlorothiazide 25 mg, and ramipril 10 mg.
- Aspirin was not in the polypill and was randomized separately at 75 mg.
- Cadila Pharmaceuticals supplied Polycap, placebo, and additional support.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.cardiovascular-polypill-containing-simvastatin.UNK.primary-prevention-without-cardiovascular-disease.prevent.MULTIUnknown > Cardiovascular polypill containing simvastatin > Unknown > Primary prevention without cardiovascular disease > Occurrence-prevention claim > Multiple: primary unresolved
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
TIPS-3 was a double-blind 2-by-2-by-2 factorial trial in intermediate-risk adults without cardiovascular disease. The polypill contained simvastatin, atenolol, hydrochlorothiazide, and ramipril, but no aspirin; aspirin 75 mg was randomized as a separate factor. The primary composite included cardiovascular death, myocardial infarction, stroke, resuscitated cardiac arrest, heart failure, or arterial revascularization. Support came from the Wellcome Trust, Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, PHRI, Hamilton Health Sciences Research Institute, St. John’s Research Institute, Cadila Pharmaceuticals, and others. Cadila supplied trial drugs and placebos and provided additional support.
Why this is classified as B (76)
One large hard-outcome RCT showed fewer events, limiting the grade to B with 76 points.
Counterpoint. Convenience does not replace individualized assessment of each component.
Rejudgment record. Cross-check applied — A large placebo-controlled event trial in intermediate-risk adults without cardiovascular disease showed a 1.1-point absolute reduction
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| First-event prevention with the aspirin-free polypill | B | Rates were 4.4% versus 5.5%. |
| Polypill plus aspirin | B | Rates were 4.1% versus 5.8%, but this was a distinct combined intervention. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Yusuf et al. 2021 TIPS-3 | International double-blind placebo-controlled factorial randomized trial | 5,713 participants; 2,861 polypill and 2,852 placebo | Wellcome Trust, Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, PHRI, Hamilton Health Sciences Research Institute, St. John’s Research Institute, Cadila Pharmaceuticals, and others; Cadila supplied trial drugs and placebos and provided additional support | Composite cardiovascular death, myocardial infarction, stroke, resuscitated cardiac arrest, heart failure, or revascularization | 126/2861 (4.4%) vs 157/2852 (5.5%), HR 0.79 (0.63-1.00), mean 4.6 years | Pivotal large hard-outcome evidence |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-07).
Final verification and publication gate: Codex · Evidence date: 2026-08-07 · Corrections: none
Cite this verdict
[Chamgap] Cardiovascular polypill x primary prevention — Evidence Grade B·76. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/cardiovascular-polypill-primary-prevention/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.